Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer
2024-515686-34-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in breast cancer, sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Objective response rate. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-515686-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515686-34-00.